Barr Receives FDA Approval for Generic Niaspan Extended-Release Tablets

Barr Pharmaceuticals has announced that its subsidiary, Barr Laboratories has received final approval from the FDA for its generic version of Kos Pharmaceutical's Niaspan 500-mg, 750-mg and 1,000-mg extended-release tablets (Niacin extended-release tablets).

The final approval follows the expiration of Kos' 30-month stay under the Hatch-Waxman patent challenge provisions and the resolution of the litigation between Barr and Kos regarding the Niaspan products.